1st Quarter - Report

WALGREEN COMPANY for WALGREEN COMPANY

Period 1st Quarter 2023 Filed Apr 20, 2023 Signed by G. Joel Baise, Director, Government Relations

Official filing
Firm
WALGREEN COMPANY
Client
WALGREEN COMPANY
Income
—
Expenses
$830,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

H.R. 7213 - Equitable Community Access to Pharmacist Services Act: Issues related to access to pharmacist services. H.J. Res. 7 - The Covid-19 National Emergency: Issues related to the public health emergency. H.R.1613 - Drug Price Transparency in Medicaid Act of 2023: Issues related to Pharmacy Benefit Manager (PBM) reform. S. 127 - Pharmacy Benefit Manager Transparency Act of 2023: Issues related to Pharmacy Benefit Manager (PBM) reform. Public Law: 109-148 - Public Readiness and Emergency Preparedness Act (PREP Act): Issues related to COVID testing and vaccinations. Clinical Trial Diversity: Issues related to access to pharmacist services.

LobbyistCovered position, as disclosed
MADELINE KAY HODGE —
KATIE L SMITH New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.J.Res. 7 (118th), H.R. 7213 (118th), S. 127 (118th), H.R. 1613 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.